Mesenchymal Stem/Stromal Cell Therapy in Atopic Dermatitis and Chronic Urticaria: Immunological and Clinical Viewpoints
October 2021
in “
Stem Cell Research & Therapy
”
TLDR Mesenchymal stem cells may effectively treat and prevent allergic skin conditions.
The review discussed the potential of mesenchymal stem/stromal cell therapy (MSCT) for treating atopic dermatitis (AD) and chronic urticaria (CU) by modulating immune responses and offering symptomatic relief. Mesenchymal stem cells (MSCs) were noted for their ability to restore immune balance, reduce allergen-specific IgE, and inhibit mast cell degranulation, suggesting effectiveness against autoimmune mechanisms. Animal studies and clinical trials, including a 2017 trial with 37 AD patients and a 2020 study with 10 CU patients, showed promising results with reduced symptoms and improved clinical scores. These findings highlighted MSCs' anti-allergic and immunomodulatory roles, suggesting their suitability for treating AD and CU, though further research was needed to fully understand their mechanisms.